Rafael Franco-Cendejas

Prof. Dr. Rafael Franco-Cendejas

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2017 in International Journal of Antimicrobial Agents
Verified
Journal Article
Closed access
MCMartha Yumiko Cruz-Muñiz
Martha Yumiko Cruz-Muñiz
LLLuis Esau López-Jacome
Luis Esau López-Jacome
MHMelissa Hernández-Durán
Melissa Hernández-Durán
RFRafael Franco-Cendejas
Rafael Franco-Cendejas
PLPaula Licona-Limón
Paula Licona-Limón
Rodolfo Garcia ContrerasRodolfo Garcia Contreras
Rodolfo Garcia Contreras

1 March 2022 in Microbial Drug Resistance
Verified
Journal Article
Closed access
Luis Esaú López-JácomeLuis Esaú López-Jácome
Luis Esaú López-Jácome
DFDiana Fernández-Rodríguez
Diana Fernández-Rodríguez
RFRafael Franco-Cendejas
Rafael Franco-Cendejas
ACAdrián Camacho-Ortiz
Adrián Camacho-Ortiz
RMRayo Morfin-Otero
Rayo Morfin-Otero
Elvira Garza-GonzálezElvira Garza-González
Elvira Garza-González
Aim: This study aims to assess the changes in antimicrobial resistance among some critical and high-priority microorganisms collected previously and during the coronavirus disease 2019 (COVID-19) pandemic in Mexico. Methods: We collected antimicrobial susceptibility data for critical and high-priority microorganisms from blood, urine, respiratory samples, and from all specimens, in which the pathogen may be considered a causative agent. Data were stratified and compared for two periods: 2019 versus 2020 and second semester 2019 (prepandemic) versus the second semester 2020 (pandemic). Results: In the analysis of second semester 2019 versus the second semester 2020, in blood samples, increased resistance to oxacillin (15.2% vs. 36.9%), erythromycin (25.7% vs. 42.8%), and clindamycin (24.8% vs. 43.3%) ( p ≤ 0.01) was detected for Staphylococcus aureus , to imipenem (13% vs. 23.4%) and meropenem (11.2% vs. 21.4) ( p ≤ 0.01), for Klebsiella pneumoniae . In all specimens, increased ampicillin and tetracycline resistance was detected for Enterococcus faecium ( p ≤ 0.01). In cefepime, meropenem, levofloxacin, and gentamicin ( p ≤ 0.01), resistance was detected for Escherichia coli ; and in piperacillin-tazobactam, cefepime, imipenem, meropenem, ciprofloxacin, levofloxacin, and gentamicin ( p ≤ 0.01), resistance was detected for Pseudomonas aeruginosa . Conclusion: Antimicrobial resistance increased in Mexico during the COVID-19 pandemic. The increase in oxacillin resistance for S. aureus and carbapenem resistance for K. pneumoniae recovered from blood specimens deserves special attention. In addition, an increase in erythromycin resistance in S. aureus was detected, which may be associated with high azithromycin use. In general, for Acinetobacter baumannii and P. aeruginosa , increasing resistance rates were detected.

26 March 2019 in PLOS ONE
Verified
Journal Article
Open access
PDF file
Elvira Garza-GonzálezElvira Garza-González
Elvira Garza-González
RMRayo Morfin-Otero
Rayo Morfin-Otero
SMSoraya Mendoza-Olazarán
Soraya Mendoza-Olazarán
PBPaola Bocanegra-Ibarias
Paola Bocanegra-Ibarias
SFSamantha Flores-Treviño
Samantha Flores-Treviño
ACAdrián Camacho-Ortiz
Adrián Camacho-Ortiz
We aimed to assess the resistance rates of antimicrobial-resistant, in bacterial pathogens of epidemiological importance in 47 Mexican centers. In this retrospective study, we included a stratified sample of 47 centers, covering 20 Mexican states. Selected isolates considered as potential causatives of disease collected over a 6-month period were included. Laboratories employed their usual methods to perform microbiological studies. The results were deposited into a database and analyzed with the WHONET 5.6 software. In this 6-month study, a total of 22,943 strains were included. Regarding Gram-negatives, carbapenem resistance was detected in ≤ 3% in Escherichia coli, 12.5% in Klebsiella sp. and Enterobacter sp., and up to 40% in Pseudomonas aeruginosa; in the latter, the resistance rate for piperacillin-tazobactam (TZP) was as high as 19.1%. In Acinetobacter sp., resistance rates for cefepime, ciprofloxacin, meropenem, and TZP were higher than 50%. Regarding Gram-positives, methicillin resistance in Staphylococcus aureus (MRSA) was as high as 21.4%, and vancomycin (VAN) resistance reached up to 21% in Enterococcus faecium. Acinetobacter sp. presented the highest multidrug resistance (53%) followed by Klebsiella sp. (22.6%) and E. coli (19.4%). The multidrug resistance of Acinetobacter sp., Klebsiella sp. and E. coli and the carbapenem resistance in specific groups of enterobacteria deserve special attention in Mexico. Vancomycin-resistant enterococci (VRE) and MRSA are common in our hospitals. Our results present valuable information for the implementation of measures to control drug resistance.

14 November 2019 in Frontiers in Microbiology
Verified
Journal Article
Open access
PDF file
LLLuis Esaú López-Jácome
Luis Esaú López-Jácome
GGGeorgina Garza-Ramos
Georgina Garza-Ramos
MHMelissa Hernández-Durán
Melissa Hernández-Durán
RFRafael Franco-Cendejas
Rafael Franco-Cendejas
DLDaniel Loarca
Daniel Loarca
Rodolfo Garcia ContrerasRodolfo Garcia Contreras
Rodolfo Garcia Contreras
Pseudomonas aeruginosa is an opportunistic bacterium associated with healthcare infections in intensive care units (ICUs), ventilator-associated pneumonia (VAP), surgical site infections, and burns. This bacterium causes 75% of death in burned patients, since it can develop a persistent biofilm associated with infections, express several virulence factors, and antibiotic-resistance mechanisms. Some of these virulence factors are proteases such as elastase and alkaline protease, or toxic metabolites such as pyocyanin and is one of the few microorganisms able to produce cyanide, which inhibits the cytochrome oxidase of host cells. These virulence factors are controlled by quorum sensing (QS). In this work, 30 P. aeruginosa clinical strains isolated from burned patients from a tertiary hospital in Mexico City were studied. Antibiotic susceptibility tests were done, and virulence factors (elastase, alkaline protease, HCN, and pyocyanin) were determined in presence of an N-acylhomoserine lactonase, AiiM able to hydrolyze a wide range of acyl homoserine lactones. The treatment reduced significantly the activities of elastase and alkaline protease, and the production of pyocyanin and HCN in all producer strains but not the secretion of toxins through the type III secretion system. Our work suggests that AiiM treatment may be an effective therapy to combat P. aeruginosa infection in burn patients.

22 April 2021 in Journal of Applied Microbiology
Verified
Journal Article
Open access
PDF file
LAL. Aguilar‐Vega
L. Aguilar‐Vega
Luis Esaú López-JácomeLuis Esaú López-Jácome
Luis Esaú López-Jácome
BFBernardo Franco
Bernardo Franco
SMS. Muñoz‐Carranza
S. Muñoz‐Carranza
NVN. Vargas‐Maya
N. Vargas‐Maya
Rodolfo Garcia ContrerasRodolfo Garcia Contreras
Rodolfo Garcia Contreras
Aim As options to treat recalcitrant bacterial infections which are increasingly limited due to multidrug‐resistant strains, searching for new, effective antibacterial compounds is necessary. One strategy is to generate treatment alternatives by drug repurposing. Methods and Results In this work, phenotypic microarrays were used for the screening of miscellaneous compounds against the growth and biofilm formation of Acinetobacter baumannii, an important emergent multidrug‐resistant opportunistic pathogen. The results showed that the phenothiazine derivatives, such as promethazine, trifluoperazine, thioridazine, and chlorpromazine, inhibited the growth of antibiotic‐sensitive and multidrug‐resistant strains (showing minimal inhibitory concentrations ranging from 0·05 to 0·6 g l−1 and minimal bactericidal concentrations ranging from 0·1 to 2·5 g l−1). All phenothiazine derivatives were active against biofilm cells (with minimal biofilm eradication concentrations ranging from 0·5 to >3 g l−1). Chlorpromazine promoted reactive oxigen species (ROS) production, and cell membrane and DNA damage. Chlorpromazine showed synergy with antibiotics such as ceftazidime, meropenem, and colistin and was an effective treatment for experimentally infected Galleria mellonella when combined with ceftazidime. Conclusions It was demonstrated that phenothiazine derivatives, especially chlorpromazine, are drugs with attractive antibacterial properties against nosocomial MDR strains of A. baumannii, by generating ROS and cell membrane and DNA damage. Significance and Impact of the Study The present study indicates that repurposing phenothiazine derivatives for treating recalcitrant infections by A. baumannii could be promising.

1 February 2019 in Burns
Verified
Journal Article
Closed access
BMBalam Muñoz
Balam Muñoz
RSRocío Suárez-Sánchez
Rocío Suárez-Sánchez
Oscar Hernández-HernándezOscar Hernández-Hernández
Oscar Hernández-Hernández
RFRafael Franco-Cendejas
Rafael Franco-Cendejas
Hernán CortésHernán Cortés
Hernán Cortés
JMJonathan J. Magaña
Jonathan J. Magaña